BRPI0607404A2 - compostos de cinolina e seu uso como moduladores de receptor de x hepático - Google Patents

compostos de cinolina e seu uso como moduladores de receptor de x hepático

Info

Publication number
BRPI0607404A2
BRPI0607404A2 BRPI0607404-9A BRPI0607404A BRPI0607404A2 BR PI0607404 A2 BRPI0607404 A2 BR PI0607404A2 BR PI0607404 A BRPI0607404 A BR PI0607404A BR PI0607404 A2 BRPI0607404 A2 BR PI0607404A2
Authority
BR
Brazil
Prior art keywords
hepatic
compounds
cinolin
receptor modulators
receptor
Prior art date
Application number
BRPI0607404-9A
Other languages
English (en)
Inventor
Baihua Hu
Jay E Wrobel
Michael D Collini
Rayomand J Unwalla
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0607404A2 publication Critical patent/BRPI0607404A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS DE CINOLINA E SEU USO COMO MODULADORES DE RECEPTOR DE X HEPáTICO. A presente invenção refere-se a moduladores à base de cinolina de receptores X hepáticos (LXRs) da fórmula (1):
BRPI0607404-9A 2005-03-01 2006-03-01 compostos de cinolina e seu uso como moduladores de receptor de x hepático BRPI0607404A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65729605P 2005-03-01 2005-03-01
PCT/US2006/007224 WO2006094034A1 (en) 2005-03-01 2006-03-01 Cinnoline compounds and their use as liver x receptor modilators

Publications (1)

Publication Number Publication Date
BRPI0607404A2 true BRPI0607404A2 (pt) 2009-09-01

Family

ID=36589080

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607404-9A BRPI0607404A2 (pt) 2005-03-01 2006-03-01 compostos de cinolina e seu uso como moduladores de receptor de x hepático

Country Status (16)

Country Link
US (1) US7700595B2 (pt)
EP (1) EP1853566A1 (pt)
JP (1) JP2008531709A (pt)
KR (1) KR20070116060A (pt)
CN (1) CN101166730A (pt)
AU (1) AU2006218661A1 (pt)
BR (1) BRPI0607404A2 (pt)
CA (1) CA2599688A1 (pt)
CR (1) CR9318A (pt)
IL (1) IL185269A0 (pt)
MX (1) MX2007010572A (pt)
NI (1) NI200700223A (pt)
NO (1) NO20074277L (pt)
RU (1) RU2007131400A (pt)
WO (1) WO2006094034A1 (pt)
ZA (1) ZA200707525B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2417078C2 (ru) 2005-05-10 2011-04-27 Лабораториз Фурнье С.А. Новое применение агонистов печеночного рецептора х
US20080070883A1 (en) * 2006-09-19 2008-03-20 Wyeth Use of LXR modulators for the prevention and treatment of skin aging
AU2007297721A1 (en) * 2006-09-19 2008-03-27 Wyeth Use of LXR agonists for the treatment of osteoarthritis
BRPI0822239A2 (pt) * 2007-12-21 2015-06-30 Wyeth Llc Composto de pirazolo[1,5-a] pirimidina
EP2882496B1 (en) 2012-08-13 2019-10-09 The Rockefeller University Treatment and diagnosis of melanoma
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
MX2022007164A (es) 2019-12-13 2022-09-12 Inspirna Inc Sales metálicas y usos de estas.
TWI773602B (zh) * 2021-11-29 2022-08-01 國立陽明交通大學 三芳基噌啉鹽化合物及其製造方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE35662B1 (en) 1970-10-16 1976-04-14 Ici Ltd Pharmaceutical compositions
GB1474399A (en) 1974-08-19 1977-05-25 Ici Ltd Cinnolin-3-yl carboxylic acids and derivatives thereof
FR2528838B1 (fr) * 1982-06-16 1985-10-11 Lipha Phenyl-5 benzodiazepines-1,3, procedes de preparation et intermediaires
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
EP0498722B1 (fr) * 1991-02-07 1997-07-30 Roussel Uclaf Dérivés bicycliques azotés, leur procédé de préparation, les intermédiaires obtenus, leur application comme médicaments et les compositions pharmaceutiques les renfermant
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ATE264323T1 (de) 1992-09-14 2004-04-15 Takeda Chemical Industries Ltd Heterocyclische verbindungen und ihre verwendung als angiotensin ii antagonisten
IL110172A (en) 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
US5834468A (en) 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
EP0876345B1 (en) 1995-10-16 2004-08-18 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds as h+-atpases
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE480521T1 (de) * 1996-10-01 2010-09-15 Kyowa Hakko Kirin Co Ltd Stickstoff enthaltende heterocyclische verbindungen
JPH10310579A (ja) 1997-03-11 1998-11-24 Sumitomo Chem Co Ltd ４−シアノシンノリンおよびその製造法
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
EP1171126A4 (en) 1999-03-10 2002-03-27 Merck & Co Inc 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASING HORMONE
EP1144416B1 (de) 1999-11-10 2005-03-02 Rodenstock GmbH Heterocyclisch annellierte indenochromenderivate
AU4738101A (en) 2000-03-17 2001-10-03 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
JP2004505966A (ja) * 2000-08-09 2004-02-26 アストラゼネカ　アクチボラグ シンノリン化合物
WO2002036734A2 (en) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
US6919351B2 (en) 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
FR2817256B1 (fr) 2000-11-27 2005-07-15 Univ Pasteur Derives de l'acides 4-hydroxybutanoique et de son homologue superieur comme ligands des recepteurs du gamma- hydroxybutyrate (ghb), compositions pharmaceutiques les contenant et utilisations pharmaceutiques
CA2446380A1 (en) 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
EP1270535A3 (de) 2001-06-20 2004-02-18 Clariant GmbH Verfahren zur Herstellung von substituierten aromatischen Verbindungen
US6632810B2 (en) 2001-06-29 2003-10-14 Kowa Co., Ltd. Cyclic diamine compound with condensed-ring groups
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1471910A2 (en) 2002-01-17 2004-11-03 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
AU2003203148A1 (en) 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1478361A2 (en) 2002-02-22 2004-11-24 PHARMACIA & UPJOHN COMPANY Arylsulfone derivatives
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
FR2842526B1 (fr) * 2002-07-16 2007-07-13 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
FR2842524B1 (fr) * 2002-07-16 2005-04-22 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
WO2004072042A2 (en) 2003-02-12 2004-08-26 Carex S.A. Quinoline derivative and their use for modulation of lxr activity
FR2856062B1 (fr) * 2003-06-12 2005-11-11 Aventis Pharma Sa Derives 3-guanidinocarbonyl-heterocycle, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
EP1684694A2 (en) * 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
AU2005269759A1 (en) * 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
MX2007002592A (es) * 2004-09-03 2007-10-10 Memory Pharm Corp Derivados 4,6 -dialcoxi - cinnolina 4 - sustituidos como inhibidores de la fosfodiesterasa 10 para el tratamiento de sindromes psiquiatricos o neurologicos.
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds

Also Published As

Publication number Publication date
JP2008531709A (ja) 2008-08-14
CA2599688A1 (en) 2006-09-08
US20060252757A1 (en) 2006-11-09
IL185269A0 (en) 2008-02-09
AU2006218661A1 (en) 2006-09-08
EP1853566A1 (en) 2007-11-14
CN101166730A (zh) 2008-04-23
KR20070116060A (ko) 2007-12-06
NI200700223A (es) 2008-07-03
ZA200707525B (en) 2009-07-29
MX2007010572A (es) 2007-10-04
WO2006094034A1 (en) 2006-09-08
RU2007131400A (ru) 2009-04-10
NO20074277L (no) 2007-11-23
US7700595B2 (en) 2010-04-20
CR9318A (es) 2007-10-23

Similar Documents

Publication Publication Date Title
BRPI0607404A2 (pt) compostos de cinolina e seu uso como moduladores de receptor de x hepático
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
BR112013004920A2 (pt) "composições pesticidas".
SV2009003376A (es) Derivados de aril isoxazolinas insecticidas
RS51646B (en) TRICYCLIC UNITS AND THEIR USE AS MODULATORS OF GLUCOCORTICOID RECEPTORS
SV2009003392A (es) Aril pirrolidinas insecticidas
ECSP10010722A (es) Compuestos orgánicos
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
BRPI0607279A2 (pt) composição compatìvel com fertilizante
CR11523A (es) Agentes fijadores y epitopos wise
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
NO20071880L (no) Diagnostic Compounds
CO6362017A2 (es) Peptidos antivirales terapeuticos
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
UY29768A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
BRPI0620229A8 (pt) formulação
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
GT200600017A (es) 4-feniltetrahidroisoquinolinas sustituidas, proceso para su preparacion, su uso como medicamento y medicamento que las comprende
MA31430B1 (fr) Formulation a liberation prolongee de nevirapine

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2211 DE 21/05/2013.